	US 11,865,141 B2
	Composition for improving, preventing or treating skin disease comprising induced pluripotency stem cell-derived mesenchymal stem cells pretreated with interferon gamma and exosomes derived therefrom
Sue Kim, Seoul (KR); and Jin Ho Yu, Seoul (KR)
Assigned to THE ASAN FOUNDATION, Seoul (KR); and UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION, Gyeongsangnam-do (KR)
Appl. No. 16/959,366
Filed by THE ASAN FOUNDATION, Seoul (KR); and UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION, Ulsan (KR)
PCT Filed Jan. 7, 2019, PCT No. PCT/KR2019/000181 § 371(c)(1), (2) Date Jun. 30, 2020, PCT Pub. No. WO2019/135645, PCT Pub. Date Jul. 11, 2019.
Claims priority of application No. 10-2018-0001979 (KR), filed on Jan. 5, 2018.
Prior Publication US 2021/0060081 A1, Mar. 4, 2021
Int. Cl. A61K 35/28 (2015.01); A61P 17/00 (2006.01); C12N 5/077 (2010.01)

CPC A61K 35/28 (2013.01) [A61P 17/00 (2018.01); C12N 5/0652 (2013.01)]

2 Claims

1. A method for treating or alleviating a skin disease selected from the group consisting of atopic dermatitis, contact dermatitis, and psoriasis, in a subject in need thereof, comprising:

administering to the subject a composition comprising (i) interferon-gamma-pretreated mesenchymal stem cells or a culture thereof, or (ii) exosomes isolated from interferon-gamma-pretreated mesenchymal stem cells or a culture thereof,

wherein the mesenchymal stem cells are induced pluripotent stem cell-derived mesenchymal stem cells (iMSC).